ArticleOncotarget2020
Prognostic value of a three-scale grading system based on combining molecular imaging with
Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- The prognostic effect of dualBMC gastroenterology · 2026Article
- The role of combined FDG and SST PET/CT in neuroendocrine tumors.Journal of neuroendocrinology · 2025Review
- Article
- Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.Military Medical Research · 2024Review
- Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers.Journal of clinical medicine · 2024Review
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
- Gastric neuroendocrine neoplasms.Nature reviews. Disease primers · 2024Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.Life (Basel, Switzerland) · 2023Review
- Dual [British journal of cancer · 2023Article
- Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.World journal of gastroenterology · 2022Review
- Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).Cancers · 2022Review
- Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.Journal of endocrinological investigation · 2022Article
- Role of CombinedDiagnostics (Basel, Switzerland) · 2022Review
- Current update on imaging for pancreatic neuroendocrine neoplasms.World journal of clinical oncology · 2021Review
- Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated on the added prognostic value of a three-scale combined molecular imaging with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.